StreetInsider.com News Articles

Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences

Wed, 29 Jul 2026 07:53:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to report its audited annual consolidated financial statements and management's discussion and analysis ("MD&A") for the fiscal years ended March 31, 2026 and 2025. All figures are reported in Canadian dollars. The Company's audited consolidated financial statements and MD&A are available on the Company's website at www.RedLight.co and under the Company's profile on SEDAR+ at www.sedarplus.ca.

Following its acquisition of Filament

Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences

Wed, 29 Jul 2026 07:53:00 -0400

Following its acquisition of Filament

Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp

Fri, 17 Jul 2026 07:50:00 -0400

Rhelion Life Sciences reflects the Company's evolution into a sharpened focused, science-driven life sciences platform dedicated to psychedelic drug discovery, development, and innovation

Toronto, Ontario--(Newsfile Corp. - July 17, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") is pleased to announce that it will be changing its corporate name to Rhelion Life Sciences Corp ("Rhelion"), marking the beginning of an exciting new chapter for the Company as it steps into its identity as a more focused science and research driven natural psychedelic drug discovery and development organization.

The rebrand, pending the Canadian Securities

Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp

Fri, 17 Jul 2026 07:50:00 -0400

Rhelion Life Sciences reflects the Company's evolution into a sharpened focused, science-driven life sciences platform dedicated to psychedelic drug discovery, development, and innovation

The rebrand, pending the Canadian Securities

Red Light Holland Announces New Filament Health PEX010 European Research Shipment

Thu, 16 Jul 2026 08:03:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The Company is pleased to update that Filament completed a shipment of PEX010 into the European Union, released through its European Qualified Person ("QP"), in

Red Light Holland Announces New Filament Health PEX010 European Research Shipment

Thu, 16 Jul 2026 08:03:00 -0400

The Company is pleased to update that Filament completed a shipment of PEX010 into the European Union, released through its European Qualified Person ("QP"), in

Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offerin

Wed, 08 Jul 2026 08:00:00 -0400

Filament Health has commenced the largest production run in its history of its standardized, patented PEX010 botanical psilocybin drug candidate, introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths to deliver the widest standardized dosing range available from any natural psilocybin drug candidate, every strength produced using the same proprietary extraction and stabilization methods.

Toronto, Ontario--(Newsfile Corp. - July 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following

Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offerin

Wed, 08 Jul 2026 08:00:00 -0400

Filament Health has commenced the largest production run in its history of its standardized, patented PEX010 botanical psilocybin drug candidate, introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths to deliver the widest standardized dosing range available from any natural psilocybin drug candidate, every strength produced using the same proprietary extraction and stabilization methods.

Filament Health to supply psilocybin drug for veterans PTSD study

Tue, 07 Jul 2026 08:14:11 -0400

Filament Health, a wholly owned subsidiary of Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF), has signed an agreement with ARQ National Psychotrauma Centre in the Netherlands to supply its botanical psilocybin drug candidate, PEX010, for a pilot clinical study focused on military veterans with post-traumatic stress disorder.

The study, titled "Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study," will use PEX010 as the investigational drug product. ARQ National Psychotrauma Centre is based in Diemen, the Netherlands, and specializes in the diagnosis and treatment of complex psychotrauma conditions, including those affecting military veterans.

According to

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre

Tue, 07 Jul 2026 08:12:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The Company is pleased to announce that Filament has signed an agreement with ARQ National Psychotrauma Centre ("ARQ"), a leading mental healthcare institute in the

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre

Tue, 07 Jul 2026 08:12:00 -0400

The Company is pleased to announce that Filament has signed an agreement with ARQ National Psychotrauma Centre ("ARQ"), a leading mental healthcare institute in the

Red Light Holland reports preclinical coca extract results for post-GLP-1 weight management

Thu, 18 Jun 2026 09:03:15 -0400

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) announced that Magdalena Biosciences, a joint venture held through its wholly owned subsidiary Filament Health Corp., has reported positive results from a preclinical study involving a coca leaf extract as a potential weight management therapy following GLP-1 drug cessation.

The 20-day study, conducted in Alberta, Canada, in collaboration with the Borgland Lab at the University of Calgary, found that a novel extract derived from coca leaves prevented weight gain in mice placed on a high-fat diet, without reducing food intake or increasing physical activity. Stephanie Borgland, PhD, served as principal investigator.

Magdalena

Red Light Holland reports preclinical coca extract results for post-GLP-1 weight management

Thu, 18 Jun 2026 09:03:15 -0400

Magdalena

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived drug development. Through the Filament acquisition, the Company also holds Filament's interest in Magdalena Biosciences, Inc. ("Magdalena"), a

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filam

Thu, 18 Jun 2026 09:01:00 -0400

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss management

Red Light Holland subsidiary signs psilocybin supply deal with Paris hospital

Mon, 08 Jun 2026 07:32:13 -0400

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) announced that its subsidiary Filament Health has signed an agreement to supply PEX010, a botanical psilocybin drug candidate, to GHU Paris Psychiatrie & Neurosciences for an academic clinical study.

The French university hospital group will use PEX010 in a randomized, double-blind, cross-over study titled "KETAPSYCHECOG: Effects of ketamine and psilocybin on behavioral and neural measures" involving healthy volunteers. The trial aims to compare behavioral and neural effects of psilocybin and ketamine.

GHU Paris, established in 2019 through the merger of three hospitals, operates 170 facilities across 94 sites in Paris and serves

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Mon, 08 Jun 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The Company is pleased to announce that Filament has signed an agreement with GHU Paris Psychiatrie & Neurosciences ("GHU Paris"), a leading French university hospital

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Mon, 08 Jun 2026 07:30:00 -0400

The Company is pleased to announce that Filament has signed an agreement with GHU Paris Psychiatrie & Neurosciences ("GHU Paris"), a leading French university hospital

Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinica

Thu, 04 Jun 2026 07:30:00 -0400

Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity, neuroinflammatory markers, and preclinical Alzheimer's disease pathology in healthy older adults.

Toronto, Ontario--(Newsfile Corp. - June 4, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting

Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinica

Thu, 04 Jun 2026 07:30:00 -0400

Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity, neuroinflammatory markers, and preclinical Alzheimer's disease pathology in healthy older adults.

Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate

Mon, 25 May 2026 08:40:00 -0400

The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.

Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company"), is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development

Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate

Mon, 25 May 2026 08:40:00 -0400

The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechani

Thu, 14 May 2026 08:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. Red Light is pleased to confirm additional shipments of Filament Health's PEX010 supporting:

Bruyère Health Research Institute ("Bruyère") – Ongoing shipments in support of the Microdose Open Label Extension